| Dr Jeffrey D Hempel, DDS | |
|
33342 Santiago Rd, Acton, CA 93510-1429 | |
| (661) 269-0610 | |
| (661) 269-4803 |
| Full Name | Dr Jeffrey D Hempel |
|---|---|
| Gender | Male |
| Speciality | Dentist |
| Location | 33342 Santiago Rd, Acton, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427275114 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 29290 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey D Hempel, DDS 33342 Santiago Rd, Acton, CA 93510-1429 Ph: (661) 269-0610 | Dr Jeffrey D Hempel, DDS 33342 Santiago Rd, Acton, CA 93510-1429 Ph: (661) 269-0610 |
News Archive
A type of exercise called pelvic floor muscle training is effective for treating adult women with urinary incontinence (the involuntary loss of urine) without risk of side effects, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ). The report also found that drug-based treatments can be effective, but the degree of benefit is low and side effects are common.
Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.
An estimated 2.5 percent of Americans — 7.5 million people — have at least one food allergy and young black children with asthma appear to be at the highest risk, according to findings from what is believed to be the largest food allergy study to date. The research was conducted by investigators at Johns Hopkins Children's Center, the National Institutes of Health and other institutions.
German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGG® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.
Accela, Inc. today announced that the California Office of Statewide Health Planning and Development (OSHPD) has selected Accela Automation software as the nexus of a comprehensive online environment that will track hospital and skilled nursing facility construction projects across the state. OSHPD's Facilities Development Division (FDD) will utilize Accela solutions to replace an existing database system, which is used to track health-facility plan review and construction; facilitate inspections and certifications; and ensure compliance with state-mandated seismic safety standards.
› Verified 7 days ago